唑来膦酸治疗原发性骨质疏松症的疗效及安全性

Efficacy and Safety of Zoledronic Acid in Treatment of Primary Osteoporosis

目的:探讨唑来膦酸治疗原发性骨质疏松症的疗效及安全性。方法:选取2014年1月—2016年1月驻马店市中心医院收治的原发性骨质疏松症患者166例作为研究对象,按随机数字表法分为A组和B组,每组83例。A组患者给予唑来膦酸静脉滴注,B组患者给予阿仑膦酸钠口服,治疗12个月后,观察两组患者的疗效及安全性。结果:A组患者的总有效率为95.18%(79/83),明显高于B组的81.93%(68/83),差异有统计学意义(P<0.05)。治疗后,A组患者腰椎(L_(1—4))、股骨颈、Ward三角区骨密度明显高于本组治疗前及B组,差异均有统计学意义(P<0.05)。A组患者不良反应发生率为4.82%(4/83),B组为6.02%(5/83),两组的差异无统计学意义(P>0.05)。结论:唑来膦酸治疗原发性骨质疏松症的疗效较好,能有效升高骨密度,安全性较高。

OBJECTIVE： To probe into the efficacy and safety of zoledronic acid in treatment of primary osteoporosis. METHODS： 166 patients with primary osteoporosis admitted into Zhumadian Central Hospital from Jan. 2014 to Jan. 2016 were selected to be divided into group A and group B via the random number table, with 83 cases in each. Group A was given azole phosphonic acid by intravenous drip, group B received allen phosphonic acid sodium orally. After treatment of 12 months, the efficacy and safety of two groups were observed. RESULTS ： The total effective rate of group A was 95. 18% （79/83）, significantly higher than that of group B I81.93% （68/83）], with statically significant difference（P 〈 0. 05）. After treatment, lumbar vertebra（L1-4）, femoral neck, Ward triangle bone density of group A increased significantly compared with before treatment and group B, with statically significant differenee（ P 〈 0. 05）. The incidence of adverse drug reactions of group A was 4. 82% （5/83）, group B was 6. 02% （5/83）, the difference was not statistically significant （ P 〉 0. 05 ）. CONCLUSIONS ： The efficacy of zoledronic acid in treatment of primary osteoporosis is significant, which can effectively increase the bone mineral density with high safety.